Earnings Call · Q1 FY2025·2025-02-10

Q1 25EPS -93.06%·Rev n/aQ4 24EPS -48.59%·Rev n/aQ3 24EPS -100.00%*·Rev n/aQ2 24EPS -100.00%*·Rev n/a⚠ consensus missing

ARROWHEAD PHARMACEUTICALS, INC. ARWR

Chris Anzalone — Chief Executive Officer

Bruce Given — Chief Medical Officer

Andy Davis — Chief Commercial Officer

James Hamilton — Head of Research or Development

Ken Myszkowski — Chief Financial Officer

−5.2%1d on move date−5.2% vs SPY3d−4.1%5d+2.6%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ARWR calls or request research access.

More ARWR calls Browse calls Request research access